Project name: Hepatitis C virus subtype 1b

Description: Daclatasvir and asunaprevir dual oral therapy is expected to achieve high sustained virological response rates in patients with HCV genotype 1b infection. However, presence of the NS5A-Y93H substitution at baseline has been shown to be an independent predictor of treatment failure for this regimen. To develop a probe-based rapid evaluation system for the drug resistant variant strain frequency, using a total of 55 sera from HCV genotype 1b-infected Japanese patients, we performed ultra-deep sequencing and compared the proportion of the variant strain with those by the probe-based method.

Data type: targeted loci

Sample scope: Multiisolate

Relevance: Medical

Last updated: 2015-02-15